Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.
Allopathic clinicians should treat local health practitioners as equal partners in cross-cultural clinical practice and express respect for traditional therapies.
AMA J Ethics. 2016;18(7):691-697. doi:
10.1001/journalofethics.2016.18.7.ecas4-1607.